Sema4 recognized for its cutting-edge precision medicine solutions that enable providers and patients to dramatically improve health outcomes
STAMFORD, CT — August 13, 2020 — Sema4, a patient-centered health intelligence company, has been recognized by CB Insights in its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world.
The 2020 CB Insights Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across several different categories. Sema4 is included in the Clinical Intelligence & Enablement category. Countries represented in the Digital Health 150 include Canada, China, Israel, France, the United Kingdom, and the United States, among others.
“This year’s Digital Health 150 is our most global ever, covering the best private healthcare companies from 17 countries. Beyond geographic diversity, these companies are innovating across the entire healthcare value chain, spanning technologies that benefit pharma & biotech companies, to payers, hospitals, insurers, and more,” said Anand Sanwal, Chief Executive Officer of CB Insights. “Last year’s Digital Health 150 winners saw numerous exits and went on to raise nearly $5 billion in investor financing after being recognized. We look forward to seeing the success of this year’s class of the best in digital health.”
Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, added: “We are delighted to be named to the 2020 CB Insights Digital Health 150. This recognition underscores that our cutting-edge solutions across women’s health, oncology, and biopharma are having a significant positive impact on both healthcare providers and patients. We look forward to continuing to apply artificial intelligence and big data analytics to further improve the diagnosis, treatment and prevention of disease.”
Through an evidence-based approach, the CB Insights research team selected the Digital Health 150 from hundreds of applications based on several factors including patent activity, investor quality, news sentiment analysis, proprietary Mosaic scores, market potential, partnerships, competitive landscape, team strength, and tech novelty. The Mosaic Score, based on CB Insights’ algorithm, measures the overall health and growth potential of private companies to help predict a company’s momentum.
Sema4’s selection in the 2020 CB Insights Digital Health 150 is just the latest accolade that the company has received over recent months. Sema4 was recognized as a 2020 Cool Vendor in Healthcare Technology by Gartner Inc., the world’s leading research and advisory company, and was named by U.S. Senator Chris Murphy (Conn.) as “Murphy’s Innovator of the Month” for its innovative approach to healthcare and for joining the fight against COVID-19. Sema4 also recently announced that it had closed an oversubscribed Series C financing of $121 million led by BlackRock at a post-money valuation of over $1 billion.
About CB Insights
At CB Insights, we believe the most complex strategic business questions are best answered with facts. We are a machine intelligence company that synthesizes, analyzes and visualizes millions of documents to give our clients fast, fact-based insights. Serving the majority of the Fortune 100, we give companies the power to make better decisions, take control of their own future, and capitalize on change.
Sema4 is a patient-centered health intelligence company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology. Centrellis™, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.